OUR PIPELINE
group
group
group
group
group

SCIENCE 02

_Flightpath is advancing platform technologies designed to address infection-driven complex diseases before they become irreversible. By selectively targeting harmful gram-negative bacteria—without disturbing the surrounding microbiome—we aim to address the root cause and potentially drive better outcomes.

<DIFFERENTIATION>

Flightpath’s therapeutic candidates are designed for precision elimination of disease-driving bacteria, without damaging the healthy microbiome.

By acting early in the disease process, within a critical “window of opportunity” before irreversible tissue damage sets in, we believe we can transform outcomes, reduce long-term morbidity and mortality, as well as the total cost of care.

<metastasis>

F. nucleatum induces neutrophil swarming and the migration of cancer epithelial cells.

Galeano Niño, J.L., Wu, H., LaCourse, K.D. et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature 611, 810–817 (2022). https://doi.org/10.1038/s41586-022-05435-0.

http://creativecommons.org/licenses/by/4.0/

<bacterial deletion>

Fusobacterium in a spheroid model of CRC undergoing "targeted bacterial deletion"

<window of opportunity>

Early intervention and the progression of Crohn’s disease.

Current evidence suggests that there may be a window of opportunity for early intervention with DMAID to change the natural progression of Crohn’s disease and to prevent or reduce future complications.

Adapted from Pariente et al. and Colombel et al. Pariente B et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17(6):1415-22. Colombel JF et al. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):351-61.

<SCIENTIFIC

rAtionale>

Opportunistic gram-negative bacteria are increasingly recognized as persistent, underappreciated drivers of complex disease. These pathogens contribute to inflammation, immune dysregulation, and tissue damage across a range of complex diseases.

—In these conditions, disease progression matters, and microbial influence often appears early. By targeting only the bacteria that drive disease, we aim to intervene before irreversible damage occurs.

Clip path frame
<our bacterial targets _are common, often drug-resistant, gram (-) pathogens or pathobionts associated with the onset and progression of complex diseases.>
VIEW OUR PIPELINE
< colorectal cancer >
< inflammatory bowel >
< periodontal >
< lyme >
< uti >
< endometriosis >
< bacterial vaginosis >

<candidates>

_Flightpath is committed to the development of a diverse set of precision drug candidates to impact diseases from multiple perspectives.

fp530
Abstract 3D molecular structure of a short chain molecule or peptide glowing blue and pink.

FP530 (Forazemin) is an orally bioavailable small molecule peptide deformylase inhibitor – PDF is an essential enzyme in gram (-) bacteria.

PDF inhibitors are bactericidal against specific keystone gram-negative pathogens that are causal in Lyme disease, periodontal disease, and reproductive tract diseases like bacterial vaginosis, endometriosis, PID, infertility and STIs, without adversely impacting most beneficial bacteria.

Some of these same commonly occurring oral pathogens are also known to translocate from the oral cavity to other parts of the body via the circulatory system, within immune cells and via the GI tract and have been implicated in life threatening cancers (e.g. colorectal cancer, oral squamous cell carcinoma, pancreatic and gastric cancer), cardiovascular and neurological diseases.

3D chemical structure with two rings.
FP385 (lolevexin) is a gut restricted, small molecule, LolCDE inhibitor that targets Escherichia Coli, Klebsiella pneumoniae and Enterobacter cloacae without disrupting healthy gut bacteria.
The LolCDE mechanism interrupts the transport of bacterial lipoproteins in Gram-negative bacteria This process is crucial for bacterial growth, antibiotic resistance, and microbe-host interactions. Disrupting this process is bactericidal to the target bacteria.
FP385 (lolevexin) is designed to target casual bacteria in GI diseases with mitigated systemic toxicity risk
The company aims to evaluate this drug candidate in AIEC (+) IBD and complicated Colorectal Cancers with intractable Klebsiella pneumoniae and / or E. coli infections (antimicrobial resistant forms).
Glowing 3D molecular structure (neurotransmitter).

FP380 is a systemic, small molecule, LolCDE inhibitor that targets Escherichia Coli, Klebsiella pneumoniae and Enterobacter cloacae without disrupting healthy gut bacteria.

By precisely targeting Klebsiella pneumoniae and E. coli, FP380 aims to address causal bacteria in complicated UTI and sepsis cases which are unresponsive to current medications due to antimicrobial resistance and safety risks.

<MARKET_
opportunities>

ON THE PATH TO DELETING A MASSIVE UNMET NEED

_Millions of people live with chronic, debilitating, and often deadly diseases rooted in persistent bacterial infections. Yet most therapies still manage symptoms. By precisely removing the bacteria driving inflammation and tissue damage, we have an opportunity to significantly reduce both disease burden and healthcare costs.

<COLORECTAL CANCER>
4.9M

_patients living with CRC globally

<COLORECTAL CANCER>
  • In 2025, there are >1.9M new cases globally with 13Bn+ spent on therapeutics
  • Over the past 20 years, incidence among young adults doubled
  • 25-30% will progress to metastasis and 90-95% will require major surgery
<Periodontal Disease>

_of adults >65 suffer from periodontal disease

~60%
<Periodontal Disease>
  • Oral diseases affect 3.5B people worldwide. Severe gum disease impacts over 1B, and in the U.S., 4 in 10 adults over 30 are affected.
  • Oral disease is linked to: Diabetes, Cardiovascular Disease, Respiratory Diseases, Adverse Pregnancy Outcomes (preterm birth and low-birth-weight infants), Cancer (kidney, pancreatic, and blood cancers), Alzheimer's Disease, Metabolic Syndrome (insulin resistance, obesity, and hypertension), rheumatoid arthritis, chronic kidney disease, and cognitive impairment.
<LYME DISEASE>
~500K

_new Lyme disease cases in the US annually

<LYME DISEASE>
  • Approximately 500K patients in the US are diagnosed with Lyme each year.
  • ~15% will develop Lyme neuroborreliosis, with neurologic involvement presenting as facial palsy, numbness, tingling, burning, “shooting” nerve pain, limb weakness, headache, neck stiffness, sensitivity to light and fever.
  • More than 1M patients in the US live with post-treatment Lyme disease.
<Complicated Urinary Tract Infections (CUTIS)>

_of UTIs are caused by bacteria resistant to standard therapies

30%
<Complicated Urinary Tract Infections (CUTIS)>
  • ~18–25 million UTI cases/year (~1.4 million complicated)
  • cUTI therapeutics market is valued around USD ~1.4B in 2025
  • While not a chronic disease, there is a high recurrence in at-risk groups.
<INFLAMmATORY BOWEL DISEASE (IBD)>
~3.1M

_new cases / year globally

<INFLAMmATORY BOWEL DISEASE (IBD)>
  • Over the past 20 years, incidence increased 55–65% and prevalence tripled worldwide (now >1% prevalence in some countries).
  • Research shows that nearly 1 IN 3 patients harbor adherent-invasive Escherichia coli (AIEC), a bacteria linked to disease progression.
<Bacterial Vaginosis

_new cases/year

35M
<Bacterial Vaginosis>
  • The primary bacteria driving bacterial vaginosis is Gardnerella vaginalis biofilm colonizations linked to increased risks for pelvic inflammatory disease, infertility, endometriosis and upper genital tract infections, contributing to chronic gynecologic morbidity.
  • 50-80% of women experience recurrence within 6 to 12 months.
  • The global bacterial vaginosis therapeutics market is ~$3Bn in 2025
< Endometriosis>
~190M

_women of reproductive age impacted globally (>10%)

internal view of the uterus and pelvis.
internal view of the uterus and pelvis.
<Endometriosis>
  • ~10 million new cases of endometriosis are diagnosed globally each year. approximately 30–50% of women with endometriosis experience infertility
  • In the United States alone, over 100,000 hysterectomies ($30-50K) are performed each year for a primary diagnosis of endometriosis.
  • The global endometriosis therapeutics market is valued around USD 2.0 billion in 2025

<publications>

Cell - Selective Antibiotic for Lyme Disease.
SOURCE

Leimer et al., A selective antibiotic for Lyme disease, Cell (2021), doi:10.1016/j.cell.2021.09.011

“A selective antibiotic for Lyme disease”

Hygromycin A cleared the B. burgdorferi infection in mice and was less disruptive to the fecal microbiome than clinically relevant antibiotics.

Nature - Gram-negative selective antibiotic.
SOURCE

Muñoz et al., A Gram-negative-selective antibiotic that spares the gut microbiome, Nature (2024), doi:10.1038/s41586-024-07502-0

“A Gram-negative-selective antibiotic that spares the gut microbiome”

Here we report the design and discovery of lolamicin, a Gram-negative-specific antibiotic targeting the lipoprotein transport system.

3D medical illustration of advanced gum disease (periodontitis) showing bone and tissue loss.
SOURCE

Yakar et al., Targeted elimination of Fusobacterium nucleatum alleviates periodontitis, Journal of Oral Microbiology (2024), doi:10.1080/20002297.2024.2388900

“Targeted elimination of Fusobacterium nucleatum alleviates periodontitis”

Hygromycin A effectively eliminates F. nucleatum from oral microbiota and significantly reduces bone loss in a mouse periodontitis model, demonstrating its potential as a targeted therapeutic agent for periodontal disease.

Microscopic slide image (histology) showing glandular tissue surrounded by inflammation and fat.
SOURCE

Muraoka et al., Fusobacterium infection facilitates the development of endometriosis through the phenotypic transition of endometrial fibroblasts, Science Translational Medicine (2023), doi:10.1126/scitranslmed.add1531

“Fusobacterium infection facilitates the development of endometriosis…”

Here, we demonstrated a pathogenic role of Fusobacterium in the formation of ovarian endometriosis. In a cohort of women, 64% of patients with endometriosis but <10% of controls were found to have Fusobacterium infiltration in the endometrium.

<Immunobiology>

“Evasion of complement and amyloid-beta by the neurotropic pathogen Borrelia burgdorferi in human 3D cultures”

This study highlights how Borrelia burgdorferi persists in human tissue-like environments by evading innate immune defenses, reinforcing the need for targeted approaches to eliminate pathogenic bacteria while preserving surrounding host and microbial ecosystems.

SOURCE

Heiland et al., Evasion of complement and amyloid-beta by the neurotropic pathogen Borrelia burgdorferi in human 3D cultures, Immunobiology (2025), doi:10.1016/j.imbio.2025.152928

Read More
<PLOS ONE>

“Active Invasion of Oral and Aortic Tissues by Porphyromonas gingivalis in Mice Causally Links Periodontitis and Atherosclerosis”

This study shows that Porphyromonas gingivalis can actively invade and persist within oral and vascular tissues, providing causal evidence that localized bacterial infection can drive systemic inflammatory disease and underscoring the importance of targeted bacterial elimination strategies.

SOURCE

Velsko et al., Active invasion of oral and aortic tissues by Porphyromonas gingivalis in mice causally links periodontitis and atherosclerosis, PLOS ONE (2014), doi:10.1371/journal.pone.0097821

Read More
<Cancer Cell>

“Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest”

Tumor-infiltrating bacteria are increasingly recognized as modulators of cancer progression and therapy resistance.

SOURCE

Galeano Niño et al., Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest, Cancer Cell (2025), doi:10.1016/j.ccell.2025.09.010

Read More
LOAD MORE PUBLICATIONS

<up next>

OUR PIPELINE

close button.
Mega Menu Logo

<TARGETED BACTERIAL DELETION>

Subtle FP Background